The Concept of CMREvaluating CMRManaging CMRDocumentation Center
Print this pageDecrease text sizeIncrease text size

Managing Cardiometabolic Risk

Effects of Weight Loss on Adipose Tissue Distribution

It is well documented that weight loss has a positive effect on all obesity-related metabolic complications (blood pressure, lipids, insulin sensitivity and glucose tolerance, inflammation, etc.). However, because intra-abdominal (visceral) fat is the fat with the strongest ties to the metabolic abnormalities of overweight/obesity, it is important to study the effects of weight loss on body fat distribution and on the amount of intra-abdominal fat in particular. Studies have shown that weight loss caused by a low-calorie diet or exercise program can significantly reduce intra-abdominal adiposity. The extent of this reduction depends on initial obesity: generally, the greater the initial amount of excess intra-abdominal fat, the more intra-abdominal fat will be reduced with weight loss. Several studies have reported that moderate weight loss (as little as 5 to 10% of initial body weight) can reduce intra-abdominal fat by 10 to 30%. Moreover, for a given amount of weight loss, exercise burns more intra-abdominal fat than caloric restriction while preserving lean body mass (skeletal muscle). It is therefore possible to reduce intra-abdominal fat without necessarily losing weight. Exercise can reduce intra-abdominal fat while increasing lean body mass, causing no change in body weight.

Document Center


A Simplified View of Victor Dzau´s Cardiovascular Continuum by Luis Miguel Ruilope, MD

A Simplified View of Victor Dzau´s Cardiovascular Continuum by Luis Miguel Ruilope, MD

More

Which factors/markers do you think will emerge as key predictors of global CMR beyond the Framingham risk score?

Which factors/markers do you think will emerge as key predictors of global CMR beyond the Framingham risk score?

More

Post-AHA 2007: Lifestyle intervention

Post-AHA 2007: Lifestyle intervention

More

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 2008;197:355-62

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 2008;197:355-62

More

Evidence for a greater relative accumulation of intra-abdominal adipose tissue (AT) in Japanese than Caucasian Americans

Evidence for a greater relative accumulation of intra-abdominal adipose tissue (AT) in Japanese than Caucasian Americans

More